Zobrazeno 1 - 2
of 2
pro vyhledávání: '"David F. Claxton"'
Autor:
Raoul Tibes, Stan Gill, Chaofeng Liu, Christoph Röllig, Stephen A. Strickland, Joseph G. Jurcic, Stuart L. Goldberg, Maria R. Baer, Alexander E. Perl, Alexander I. Spira, Andreas Neubauer, Gary J. Schiller, Mark R. Litzow, Richard A. Larson, Catherine C. Smith, Jessica K. Altman, Harry P. Erba, Mark J. Levis, Erkut Bahceci, Giovanni Martinelli, Robert K. Stuart, Eunice S. Wang, Jorge E. Cortes, David F. Claxton, Celalettin Ustun, Ellen K. Ritchie
Publikováno v:
The Lancet. Oncology, vol 18, iss 8
The Lancet. Oncology
The Lancet. Oncology
Summary Background Internal tandem duplication mutations in FLT3 are common in acute myeloid leukaemia and are associated with rapid relapse and short overall survival. The clinical benefit of FLT3 inhibitors in patients with acute myeloid leukaemia
Autor:
Parameswaran Venugopal, Elias Jabbour, Stephen A. Strickland, Karen Seiter, Martha Arellano, Gary J. Schiller, Steven Coutre, David F. Claxton, Wendy Stock, Selina M. Luger, Lori J. Maness, Meir Wetzler, Stuart L. Goldberg, Hagop M. Kantarjian, William Plunkett, Stefan Faderl, Judy Chiao, Guillermo Garcia-Manero
Publikováno v:
The Lancet Oncology. 13:1096-1104
Summary Background Available treatments for acute myeloid leukaemia (AML) have limited durable activity and unsatisfactory safety profiles in most elderly patients. We assessed the efficacy and toxicity of sapacitabine, a novel oral cytosine nucleosi